Autolus’ solid tumour CAR-Ts will have ‘off switch’
Up and coming immunotherapy company Autolus has published details of an ‘off switch’ safety features in its next generation CAR-Ts.
Up and coming immunotherapy company Autolus has published details of an ‘off switch’ safety features in its next generation CAR-Ts.
The UK is a great place for early-stage research – but NHS red tape and market access remain major barriers.